Bertrand Routy

Centre Hospitalier de l’Université de Montréal — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index6.9kcitations115works12.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gut microbiota and health(47), Cancer Immunotherapy and Biomarkers(43), Pancreatic and Hepatic Oncology Research(11), Clostridium difficile and Clostridium perfringens research(10), Immune Cell Function and Interaction(9)

Publications114 total

Metagenomics and culturomics reveal the dual role of gut microbiome in the development of immune-related toxicities and immune checkpoint inhibitors efficacy in cancer
2025Open Access
Fecal microbiota transplantation to reduce immune activation in ART-treated people with HIV with low CD4/CD8 ratio: protocol for the single-blind, randomized, placebo-controlled Gutsy study (CIHR/CTN PT038)
Trials·2025Open Access
Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence
Nature Cancer·2025
Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer
Nature Communications·2025· 2 citedOpen Access
Obesity-associated checkpoint blockade sensitivity is regulated by the diet-microbiota-immunity axis 4468
The Journal of Immunology·2025Open Access
272 The gut microbiome of non-atopic Chronic Hand Eczema (CHE) patients is enriched in immuno-modulatory bacteria species and distinct from that of atopic-CHE and healthy subjects
Journal of Investigative Dermatology·2025
20MO Hallmarks of gut health influence toxicity and survival outcomes after immune-checkpoint inhibitors
ESMO Open·2025Open Access
CN104 Impact of fecal microbial transplantation on quality of life in patients with non-small cell lung cancer or melanoma undergoing immune checkpoint inhibitors
Annals of Oncology·2025
Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer
OncoImmunology·2025· 3 citedOpen Access
The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development
Nature Reviews Drug Discovery·2025· 27 cited
Association of intestinal exfoliome and Prevotellaceae with toxicity and clinical outcome during immune-checkpoint blockade.
Journal of Clinical Oncology·2025· 1 cited
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study
Lung Cancer·2025· 2 cited
Abstract 2020: Fibroblast derived type III collagen pro-peptides (PRO-C3) in plasma is associated with outcome for patients with NSCLC treated with anti-PD1 plus chemotherapy
Cancer Research·2025
Abstract 2210: Microbiome profiling reveals that fecal microbiota transplantation (FMT) modulates response and toxicity when combined with immunotherapy in patients with lung cancer and melanoma (FMT-LUMINate NCT04951583)
Cancer Research·2025· 6 cited
Impact of the ONCOBIOME network in cancer microbiome research
Nature Medicine·2025· 13 citedOpen Access
Exchange transfusion and pre‐filter apheresis dilution for hyperviscosity syndrome refractory to conventional therapeutic plasma exchange in a patient with <scp>IgA</scp> multiple myeloma
Transfusion·2025Open Access
346P: Multi-omics approach to identify factors underlying antibiotics (ABX)-mediated immunosuppression in a prospective trial of cancer immunotherapy
Journal of Thoracic Oncology·2025Open Access
Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study)
Current Oncology·2025· 4 citedOpen Access
1260 DAV132 colon-targeted adsorbent prevents antibiotic-related dysbiosis in human volunteers and fecal microbiota transplantation mitigates anti-PD-1 resistance in avatar models
Regular and Young Investigator Award Abstracts·2024Open Access
Correction: Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance
Molecular Cancer·2024· 1 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Laurence Zitvogel(22), Lisa Derosa(20), Guido Kroemer(16), Corentin Richard(16), Arielle Elkrief(15), Meriem Messaoudene(14), François Ghiringhelli(9), Nicola Segata(8), Romain Daillère(6), Marine Fidelle(6), Carolina Alves Costa Silva(6), Safae Terrisse(6), Antoine Desîlets(6), Laurence Albigès(5), Taiki Hakozaki(5), Caroline Truntzer(5), Jean‐Pierre Routy(5), María Paula Roberti(4), Andrew Maltez Thomas(4), Valerio Iebba(4)